SPRB vs. ME, HOWL, IPSC, AADI, STTK, CTMX, VHAQ, CNTX, QNCX, and KRON
Should you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include 23andMe (ME), Werewolf Therapeutics (HOWL), Century Therapeutics (IPSC), Aadi Bioscience (AADI), Shattuck Labs (STTK), CytomX Therapeutics (CTMX), Viveon Health Acquisition (VHAQ), Context Therapeutics (CNTX), Quince Therapeutics (QNCX), and Kronos Bio (KRON). These companies are all part of the "pharmaceutical products" industry.
Spruce Biosciences vs.
23andMe (NASDAQ:ME) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, community ranking, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.
Spruce Biosciences has lower revenue, but higher earnings than 23andMe. Spruce Biosciences is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks.
23andMe currently has a consensus target price of $9.40, suggesting a potential upside of 288.43%. Spruce Biosciences has a consensus target price of $2.38, suggesting a potential upside of 465.48%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than 23andMe.
36.1% of 23andMe shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 26.3% of 23andMe shares are owned by company insiders. Comparatively, 9.1% of Spruce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
23andMe has a net margin of -183.39% compared to Spruce Biosciences' net margin of -555.23%. Spruce Biosciences' return on equity of -62.10% beat 23andMe's return on equity.
23andMe has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500.
In the previous week, 23andMe had 5 more articles in the media than Spruce Biosciences. MarketBeat recorded 6 mentions for 23andMe and 1 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.00 beat 23andMe's score of -0.24 indicating that Spruce Biosciences is being referred to more favorably in the news media.
Spruce Biosciences received 27 more outperform votes than 23andMe when rated by MarketBeat users. Likewise, 54.93% of users gave Spruce Biosciences an outperform vote while only 50.00% of users gave 23andMe an outperform vote.
Summary
Spruce Biosciences beats 23andMe on 12 of the 17 factors compared between the two stocks.
Get Spruce Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spruce Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:SPRB) was last updated on 2/22/2025 by MarketBeat.com Staff
Free SPRB Stock Alerts